SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
(Amendment No. 1)
CURRENT REPORT Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 27, 2017
|(Exact Name of Registrant as Specified in Its Charter)|
|(State or Other Jurisdiction of Incorporation or Organization)||(Commission File Number)||(IRS Employer Identification No.)|
483 Bay Street, N105
(Address of Principal Executive Offices)
|Registrant’s Telephone Number, Including Area Code: (416) 640-7887|
|(Former Name or Former Address, if Changed Since Last Report)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|o||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|o||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|o||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|o||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
On February 27, 2017, Bionik Laboratories Corp. filed a Current Report on Form 8-K (the “Original 8-K”) to file a press release announcing that it has appointed Malcolm G. Bock as Vice President of Engineering (the “Press Release”). The Press Release was inadvertently omitted from the Original 8-K.
This Current Report on Form 8-K/A amends the Original 8-K to include the Press Release described under Item 9.01 below.
|Item 8.01||Other Events|
On February 27, 2017, Bionik Laboratories Corp. (the “Registrant”) issued a press release announced today that it has appointed Malcolm G. Bock as Vice President of Engineering.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
|Item 9.01||Financial Statements and Exhibits|
|99.1||Press Release dated February 27, 2017|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: February 27, 2017
|BIONIK LABORATORIES CORP.|
|By:||/s/ Leslie Markow|
|Title:||Chief Financial Officer|